[[{“value”:”
Lupus is the lead autoimmune indication for Artiva Biotherapeutics, which has an early-stage clinical trial underway. Artiva’s allogeneic cell therapies are based on natural killer cells.
The post Artiva’s IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases appeared first on MedCity News.
“}]]
